A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world
and causes death of about 600000~1000000 people each year. Since 1990s, hepatic carcinoma has
become the second carcinoma killer in China. Surgical resection or liver transplantation is
the only method possibly able to cure hepatic carcinoma. However, due to multiple tumors or
poor hepatic function reserve in cirrhosis, surgical treatment is suitable for only a small
portion of patients (11.9%-30.1%). Therefore, in clinical practice, transarterial
chemoembolization (TACE) or transarterial embolization (TAE) is a preferential and standard
treatment of unresectable advanced hepatic carcinoma and has notable advantages in
controlling local tumors of the liver. Hepatic arterial infusion of oxaliplatin after TACE
can significantly increase the local doses of chemotherapeutic agents in the liver, kill
micrometastases and residual foci after embolization and demonstrate outstanding efficacy for
treating concomitant portal and hepatic vein tumor thrombi. S-1 is a chemotherapeutic agent
with convenient use and definite efficacy and, when used concomitantly with TACE,
theoretically can not only effectively control intrahepatic foci but also prevent and control
extrahepatic metastatic foci. However, this hasn't been verified in clinical application.
This study is intended to investigate efficacy and safety of the combination treatment so as
to provide a more effective and safety way for treating patients with advanced hepatic
carcinoma (Barcelona stage-C patients with concomitant portal vein tumor thrombi or
extrahepatic metastasis).